Royal Prima PT (PRIM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Royal Prima PT (PRIM) has a cash flow conversion efficiency ratio of 0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp1.86 Billion ≈ $108.71K USD) by net assets (Rp955.60 Billion ≈ $55.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Royal Prima PT balance sheet quality to measure how much of total assets are equity-financed.
Royal Prima PT - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Royal Prima PT's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Royal Prima PT earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Royal Prima PT Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Royal Prima PT ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Magna Finance Tbk
JK:MGNA
|
-0.020x |
|
Resverlogix Corp.
TO:RVX
|
0.011x |
|
Kumbi Corporation
KO:008870
|
0.059x |
|
KR1 PLC LS -0019
F:K4H
|
N/A |
|
Diamond Citra Propertindo PT
JK:DADA
|
0.016x |
|
Cherrybro co.Ltd
KQ:066360
|
0.064x |
|
Daishin Information & Communications Co.Ltd
KQ:020180
|
-0.060x |
|
Victor Group Holdings Ltd
AU:VIG
|
0.072x |
Annual Cash Flow Conversion Efficiency for Royal Prima PT (2014–2024)
The table below shows the annual cash flow conversion efficiency of Royal Prima PT from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Royal Prima PT market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Rp962.38 Billion ≈ $56.39 Million |
Rp46.98 Billion ≈ $2.75 Million |
0.049x | +125.21% |
| 2023-12-31 | Rp981.10 Billion ≈ $57.49 Million |
Rp21.27 Billion ≈ $1.25 Million |
0.022x | -1.33% |
| 2022-12-31 | Rp982.66 Billion ≈ $57.58 Million |
Rp21.59 Billion ≈ $1.27 Million |
0.022x | -90.97% |
| 2021-12-31 | Rp964.21 Billion ≈ $56.50 Million |
Rp234.54 Billion ≈ $13.74 Million |
0.243x | +259.56% |
| 2020-12-31 | Rp889.35 Billion ≈ $52.11 Million |
Rp60.16 Billion ≈ $3.53 Million |
0.068x | +1830.15% |
| 2019-12-31 | Rp851.17 Billion ≈ $49.88 Million |
Rp2.98 Billion ≈ $174.81K |
0.004x | -91.58% |
| 2018-12-31 | Rp848.87 Billion ≈ $49.74 Million |
Rp35.33 Billion ≈ $2.07 Million |
0.042x | -53.08% |
| 2017-12-31 | Rp250.42 Billion ≈ $14.67 Million |
Rp22.22 Billion ≈ $1.30 Million |
0.089x | -96.16% |
| 2016-12-31 | Rp12.13 Billion ≈ $710.64K |
Rp28.02 Billion ≈ $1.64 Million |
2.310x | +135.31% |
| 2015-12-31 | Rp722.89 Million ≈ $42.36K |
Rp-4.73 Billion ≈ $-277.14K |
-6.543x | -274.24% |
| 2014-12-31 | Rp-2.10 Billion ≈ $-123.29K |
Rp3.68 Billion ≈ $215.54K |
-1.748x | -- |
About Royal Prima PT
PT Royal Prima Tbk engages in providing hospital services in Indonesia. The company operates its hospitals under the Royal Prima Medan, Royal Prima Jambi, and RSU Royal Prima Marelan names. It provides health services, such as emergency, outpatient, inpatient, laboratorium, radiology, medical rehab, pharmacy, and MCU; and general surgery, internist, VCT, ICU, cardiology, urology, haemodialysis, m… Read more